Pulse Biosciences, Inc. Overview
Pro stress-test →Pulse Biosciences is a novel bioelectric medicine company developing proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for surgical and dermatological applications. The company commercializes the CellFX System, a multi-application platform that uses nano-pulse electrical energy to non-thermally clear cells while preserving adjacent tissue, addressing unmet clinical needs across multiple therapeutic areas.
Strategic Profile
Pro stress-test →Positioned as the pioneer in bioelectric medicine with proprietary nsPFA technology that creates a differentiated therapeutic approach. The company employs a utilization-based revenue model with the CellFX platform designed for multi-application expansion from dermatology into cardiac (atrial fibrillation) and other surgical specialties, creating multiple growth vectors.
Competitive Landscape
Pro stress-test →Pulse Biosciences operates in an emerging bioelectric medicine space with limited direct competitors currently commercializing similar technology. In adjacent markets, the company competes with traditional ablation/surgical device companies (e.g., Hologic, Medtronic) and dermatology device manufacturers in specific applications, though the nsPFA platform's unique mechanism offers differentiation.
Industry Context
Pulse Biosciences, Inc. operates in Medical Devices / Bioelectric Medicine / Surgical Equipment.
Key facts
Founded: 2014 · Headquarters: Miami, Florida · Employees: N/A · Revenue: N/A · Market cap: $1.03B